Applied UV Receives Initial Purchase Orders in Excess of $850,000 from 3Sixty Biopharmaceuticals, its Exclusive Distributor for Airocide(R) Air Purification Systems for the Continent of Africa

June 18, 2021 8:31 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Initial order is part of $3.5 million minimum first year purchase commitment of Airocideョ systems

MOUNT VERNON, NY / ACCESSWIRE / June 18, 2021 / Applied UV, Inc. (NASDAQ: AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced that it has received orders in excess of $850,000 for its Airocideツョ consumer and commercial air purification systems from 3Sixty Biopharmaceuticals (Pty) Ltd. ("3Sixty"), the Company's exclusive distributor within the continent of Africa. 3Sixty is one of the largest black owned companies in South Africa with a primary focus on the market that addresses the healthcare crisis due to the global pandemic.

Under the terms of the agreement, 3Sixty agreed to an upfront binding purchase commitment of a minimum of $3.5 million of Airocideツョ systems over the initial one-year term of the agreement. After the initial term, both parties agreed to assess opportunities to expand the product line to include the SteriLumen platform of connected UVC devices for infection control in and around high-traffic areas.

"Our partnership with 3Sixty for distribution of the Airocideツョ brand is off to a very strong start with receipt of this substantial initial purchase order," said Q Saeed, CEO of Applied UV. "3Sixty's has made a significant commitment to provide its customers with tested and proven solutions that will help reopen economies across Africa. With its scale, infrastructure, and experience, we believe they are the right partner to make the Airocideツョ system a market leader in Africa."

Airocideツョ System
The Airocide" System, originally developed by NASA with assistance from the University of Wisconsin at Madison, is an airborne pathogen killing technology that uses a patented combination of UVC and a proprietary, titanium dioxide based photocatalyst. Listed as an FDA Class II Medical device, the Airocide" technology is clinically proven and field tested to kill/remove/eliminate airborne pathogenic and non-pathogenic microorganisms, allergens, odors and harmful VOCs in a variety of applications and industries including healthcare, hospitality, grocery chains, wineries, commercial real estate, schools, dental offices and homes. Airocideツョ air purifiers are available at www.airocide.com.

About 3Sixty Biopharmaceuticals (Pty) Ltd.
3Sixty Biopharmaceuticals (Pty) Ltd is a South African company based in Johannesburg, the commercial hub of South Africa. The company is committed to the development and commercialization of South African intellectual property and it seeks to achieve this either by itself or through collaboration with principals both from the private and/or public sector.

About Applied UV
Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection" applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide" platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocideツョ products for air purification, developed by NASA and FDA Cleared as class II medical devices, utilize a proprietary photo-catalytic bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous pathogens, destructive VOCs and biological gasses into harmless water vapor without producing ozone or other harmful byproducts. Airocideツョ applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, and homes.

For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; and, https://munnworks.com/.

Forward-Looking Statements
The information contained herein may contain "forwardテ「ツツ人ooking statements." Forwardテ「ツツ人ooking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forwardテ「ツツ人ooking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forwardテ「ツツ人ooking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forwardテ「ツツ人ooking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forwardテ「ツツ人ooking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forwardテ「ツツ人ooking statements to conform these statements to actual results.

Applied UV Investor Relations
TraDigital IR
Kevin McGrath
TraDigital IR
+1-646-418-7002
kevin@tradigitalir.com

SOURCE: Applied UV, Inc.



View source version on accesswire.com:
https://www.accesswire.com/652218/Applied-UV-Receives-Initial-Purchase-Orders-in-Excess-of-850000-from-3Sixty-Biopharmaceuticals-its-Exclusive-Distributor-for-AirocideR-Air-Purification-Systems-for-the-Continent-of-Africa



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Accesswire, Press Releases

Related Entities

Definitive Agreement, FDA